Navigation Links
New compound discovered that rapidly kills liver cancer
Date:3/14/2012

Richmond, Va. (March 13, 2012) Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue. The compound, Factor Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene originally discovered by a team of researchers led by Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey Cancer Center, Blick Scholar and assistant professor in the Department of Human and Molecular Genetics and member of the VCU Institute of Molecular Medicine at the VCU School of Medicine.

Recently published in the journal Proceedings of the National Academy of Sciences, the study demonstrates that HCC cells have what is known as an "oncogene addiction" to the transcription factor Late SV40 Factor (LSF). Oncogene addiction is a term used when a cancer cell is found to be dependent on a single gene to survive. Using the compound Factor Quinolinone Inhibitor 1 (FQI1), the scientists prevented LSF from binding to HCC DNA during the transcription process, which is the first step in a series of actions that lead to cell division and duplication. This action caused rapid HCC cell death in laboratory experiments and a dramatic reduction in tumor growth in mouse models with no observable toxicity to normal liver cells.

"We may be on the verge of developing a new, effective drug for liver cancer," said Sarkar. "In the last 2 to 3 years, we demonstrated the role of LSF in liver cancer and have been screening over 110,000 compounds to identify the ones that inhibit LSF function. We identified FQI1 as one of a class of effective compounds, but we never anticipated it would work this well."

Sarkar discovered LSF's role in liver cancer in 2010 when he demonstrated significantly higher LSF levels in HCC patients in comparison to healthy individuals, and showed that inhibition of LSF reduced the progression of HCC in laboratory experiments. This finding led to the collaboration between VCU and Boston University that resulted in the discovery of FQI1.

Now that FQI1 has been identified, pharmacokinetic studies are being conducted to determine how the drug behaves in the human body. Once the scientists have determined how the drug is absorbed, distributed, metabolized and eliminated from the body, they will work with clinicians to translate their findings into phase I clinical trials in patients with liver cancer.

"We have proven this compound is effective and nontoxic in living animals," said Sarkar. "While we won't know how FQI1 reacts in humans until the first clinical trial, we are very excited by our findings and hope they lead to a new drug for a disease that is currently very difficult to treat."


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. NMR sheds new light on polymorphic forms in pharmaceutical compounds
2. New class of compounds stops disease-fueling inflammation in lab tests
3. Compounds in mate tea induce death in colon cancer cells
4. Cancer-killing compound spares healthy cells
5. BUSM researchers identify novel compound to halt virus replication
6. Tumor-targeting compound points the way to new personalized cancer treatments
7. New compound defeats drug-resistant bacteria
8. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
9. Scripps Research scientists identify new class of antimalarial compounds
10. Compound found in common wart treatment shows promise as leukemia therapy
11. Mushroom compound appears to improve effectiveness of cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices ... the first ANSI-approved GMP standard for dietary supplements this spring, is hiring ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar 29, 2017 Research and Markets has ... Forecast to 2023" report to their offering. ... The ablation device global market ... $20,995.5 million by 2023. Ablation is the minimally ... purposes, from cancerous or diseased tissue removal, to the removal of ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics ... today the appointment of Cynthia L. McHenry ... will be responsible for leading Dynatronics manufacturing, distribution, ... will report to Dynatronics, CEO Kelvyn H. ... concludes an extensive search process conducted by the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, ... of USD 55.8 billion by 2025. The projection takes into consideration the ... and a more open approach towards cannabis products around the world. In ... , North Dakota , Ohio , ...
Breaking Medicine Technology: